Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...910111213141516171819...170171»
  • ||||||||||  rivaroxaban / Generic mfg.
    Trial completion date, Trial primary completion date:  Rivaroxaban in Left Ventricular Thrombus (clinicaltrials.gov) -  Nov 27, 2023   
    P4,  N=320, Recruiting, 
    Trial completion date: May 2023 --> Jan 2024 | Trial primary completion date: May 2023 --> Dec 2023
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo, Bevyxxa (betrixaban) / AstraZeneca
    Trial completion date, Trial primary completion date:  CORRAL-AF: Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF (clinicaltrials.gov) -  Nov 18, 2023   
    P=N/A,  N=2931, Not yet recruiting, 
    Dabigatran was associated with better clinical outcomes than rivaroxaban in patients with anemia or thrombocytopenia but not in those with anemia and thrombocytopenia. Trial completion date: Aug 2033 --> Dec 2033 | Trial primary completion date: Aug 2028 --> Dec 2028
  • ||||||||||  Fragmin (dalteparin sodium) / Pfizer, Eisai, Innohep (tinzaparin) / LEO Pharma
    Trial initiation date:  THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) (clinicaltrials.gov) -  Nov 18, 2023   
    P4,  N=6660, Not yet recruiting, 
    However, this still needs validation by further studies particularly among patients with morbid obesity. Initiation date: Oct 2023 --> Jan 2024
  • ||||||||||  rivaroxaban / Generic mfg., warfarin / Generic mfg., apixaban / Generic mfg.
    Journal:  Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Obesity. (Pubmed Central) -  Nov 17, 2023   
    Limitations of this study include the retrospective single-center study design. There was a comparable risk of bleeding and recurrent VTE between DOACs and warfarin in patients initiated on therapy for VTE.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Review, Journal, Surgery:  Bleeding and thromboembolic risk in patients under anticoagulant therapy receiving oral surgery: a systematic review. (Pubmed Central) -  Nov 16, 2023   
    The results of both treatment categories (continuous versus discontinuous anticoagulant and continuous versus interruption and switch to bridging therapy) showed no significant differences in terms of bleeding events. However, the use of scores that assess the risk of thrombosis and bleeding can assist surgeons in anticipating the degree of postoperative complications and making informed treatment decisions.
  • ||||||||||  rivaroxaban / Generic mfg.
    Management of Femoral and Ilioinguinal Neuropathy Due to Iliacus Hematoma in Patient on Chronic Anticoagulation: A Case Report () -  Nov 16, 2023 - Abstract #AAPMR2023AAPMR_470;    
    Case Diagnosis: 77 year old male with history of atrial fibrillation on chronic Rivaroxaban develops femoral and ilioinguinal neuropathy secondary to right iliacus hematoma.Case Description or Program Description: The patient presented with sudden-onset right-sided hip pain upon repositioning himself at home... Prompt identification and drainage of Iliacus hematoma must be considered in a patient presenting with abrupt-onset hip pain on chronic anticoagulation in efforts to preserve nerve function.
  • ||||||||||  Review, Journal:  Potentially active compounds that improve PAD through angiogenesis: A review. (Pubmed Central) -  Nov 15, 2023   
    This paper focuses on the therapeutic effect of natural products (Salidroside, Astragaloside IV, etc.) and synthetic compounds (Cilostazol, Dapagliflozin, etc.)...Overall, these exogenous compounds have promising therapeutic potential for PAD. This study aims to summarize the potential active compounds, provide a variety of options for the search for drugs for the treatment of PAD, and bring light to the treatment of patients.
  • ||||||||||  rivaroxaban / Generic mfg., amiodarone / Generic mfg.
    Journal:  Combination of Rivaroxaban and Amiodarone Increases Bleeding in Patients With Atrial Fibrillation. (Pubmed Central) -  Nov 14, 2023   
    The combination of rivaroxaban and amiodarone increased the risk of bleeding in patients with atrial fibrillation, especially clinically relevant nonmajor and minor bleeding. Physicians prescribing rivaroxaban and amiodarone together should be concerned about an increase in the risk of nonmajor bleeding.
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    Journal:  Inappropriate dosing of direct oral anticoagulants: findings from a clinical vignette study and physician survey. (Pubmed Central) -  Nov 13, 2023   
    Furthermore, prescribers who were more confident in DOAC prescribing, and were more worried about the risk of stroke, were significantly less likely to inappropriately underdose. These findings suggest that all prescribers, regardless of speciality, may benefit from education and training to raise awareness of the risks associated with inappropriate DOAC underdosing.
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Extensive arm skin necrosis following administration of unfractionated heparin. (Pubmed Central) -  Nov 10, 2023   
    The patient was discharged in good condition after completing treatment for CIDP without any need for surgical removal of the necrotic tissue. Extensive skin necrosis, as a result of HIT, requires immediate discontinuation of UH and substitution of a nonheparin-based anticoagulation treatment.
  • ||||||||||  rivaroxaban / Generic mfg., clopidogrel / Generic mfg.
    Journal:  Thromboembolic complications during and after embolization of unruptured aneurysms: A chronological outcome in periprocedural thromboembolic events. (Pubmed Central) -  Nov 9, 2023   
    Thromboembolic events developed at a certain rate; thus, rivaroxaban was administered with single-antiplatelet therapy (SAPT) to improve thromboembolic results (Phase 2), showing better outcomes than in Phase 1...Ischemic complications were evaluated in each phase or compared between the DAPT group and the direct oral anticoagulant (DOAC) with the clopidogrel (DOAC+SAPT) group...Therefore, accumulated experience or a learning curve could not explain the results. DOAC administration might decrease the risk of these events, but further accumulation of evidence or prospective investigation is warranted.
  • ||||||||||  rivaroxaban / Generic mfg.
    Enrollment open, Trial initiation date:  Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty (clinicaltrials.gov) -  Nov 8, 2023   
    P=N/A,  N=120, Recruiting, 
    DOAC administration might decrease the risk of these events, but further accumulation of evidence or prospective investigation is warranted. Not yet recruiting --> Recruiting | Initiation date: Feb 2023 --> May 2022
  • ||||||||||  rivaroxaban / Generic mfg.
    Review, Journal:  Vascular protection with rivaroxaban in the comprehensive management of atrial fibrillation. (Pubmed Central) -  Nov 7, 2023   
    Moreover, in the AF population, additional to its ability to reduce the risk of thromboembolic complications, rivaroxaban is associated with a lower risk of myocardial infarction, major adverse cardiac and limb events, and vascular mortality in patients with diabetes, also attenuating renal impairment during follow-up. These findings suggest that rivaroxaban may provide a comprehensive vascular protection in patients with AF.
  • ||||||||||  rivaroxaban / Generic mfg., enoxaparin sodium / Generic mfg., apixaban / Generic mfg.
    Treatment Complications of Venous Thromboembolism in Patients with Central Nervous System Tumors (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_5448;    
    However, our data did not demonstrate a statistically significant difference in complication rates between these 3 anticoagulants. These findings indicate a need for future large-scale prospective investigations to determine optimal treatment in this high-risk patient population.
  • ||||||||||  rivaroxaban / Generic mfg.
    Utilization of International Normalized Ratio-Derived Formula to Predict Plasma Rivaroxaban Level  (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_5441;    
    These findings indicate a need for future large-scale prospective investigations to determine optimal treatment in this high-risk patient population. Plasma rivaroxaban level can be calculated from prediction formula by INR value with satisfactory accuracy and the INR cut-off value derived from it can be used to guide the decision for administration of reversal agents with excellent sensitivity and specificity.
  • ||||||||||  rivaroxaban / Generic mfg., dexamethasone / Generic mfg.
    Efficacy and Safety of Rivaroxaban As Thromboprophylaxis in Newly Diagnosed Multiple Myeloma Patients Receiving Immunomodulatory and Dexamethasone Based Treatment: Comorbidities Risk Adapted... (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_5440;    
    There are multiple scores for risk stratification (IMPEDE and SAVED for example), that give different points for the same variable and can be classified in low or high risk depending which is used, the same patient can receive Aspirin in one score or LMWH in the other...A very high risk patients group will be considered for Rivaroxaban in dose of 15 or 20 mg in following studies. As a final statement, these results complement our first report and give more solid evidence in the efficacy and safety of Rivaroxaban as thromboprophylaxis in Multiple Myeloma patients with IMiDs-Dex based triplet induction and maintenance with IMiDs.
  • ||||||||||  Heavy Menstrual Bleeding in Adolescents on Direct Oral Anticoagulants (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_5431;    
    Studies reporting on anticoagulation usage should more report on outcomes such as all-cause mortality after bleeding events to better characterize the potential harms of therapy. Background Direct oral anticoagulants (DOACs)
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    Extended Full Dose Versus Low Dose Direct Oral Anticoagulants in Cancer and Overweight Patients (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_1674;    
    Although the sample size limits the precision of this analysis, we did not find statistically significant increases in VTE recurrence with low dose DOACs in either cancer patients or with elevated body weight. We did find CRNMB but not MB was observed more frequently in weights above 120kg, possibly from unadjusted confounding in this unadjusted analysis.
  • ||||||||||  rivaroxaban / Generic mfg.
    HDAC Inhibitor CS014 Attenuates Thrombosis Alone and in Combination with Rivaroxaban without Increased Risk of Bleeding (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_1589;    
    The data presented here suggests that while CS014 and rivaroxaban are each effective antithrombotic agents, they work well together to minimize clot formation without altering coagulation or clotting compared to rivaroxaban alone. Hence, CS014 has the potential to enrich the toolbox of anticoagulant therapies in patients with a high risk of thrombotic events.
  • ||||||||||  Xarelto (rivaroxaban) / J&J, aspirin / Generic mfg., warfarin / Generic mfg.
    Trial completion date, Trial primary completion date, HEOR:  PEPPER: Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement (clinicaltrials.gov) -  Nov 1, 2023   
    P4,  N=20000, Recruiting, 
    While these findings should be confirmed with randomized studies, they may have implications for anticoagulant selection. Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2023 --> Jul 2025